Franklin W. Huang

Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (18)

Year:

2026

The effects of cis-regulatory alterations in prostate cancer are insufficiently characterized, presenting an opportunity to discover driver genes and therapeutic targets. To comprehensively study these effects, we identify genes undergoing allele-specific expression (ASE) in localized prostate cancer and metastatic castration-resistant prostate cancer (mCRPC) samples. By defining recurrent ASE events across prostate tissue and tumor-enriched ASE, we develop CASEDI, a computational framework for prioritizing cancer drivers by integrating ASE and clinical data. CASEDI reveals genes showing recurrent ASE and altered expression in prostate cancer, including AR-regulated and oncogenic ACSM1. mCRPC samples show enrichment of ASE in DNA repair, resistance pathways, and oncogenes and increased frequency of monoallelic expression (MAE) compared with localized tumors. We define an mCRPC gene signature based on MAE status that identifies a subgroup of localized patients with worse prognosis. Using ASE analysis, we expand the landscape of cis-regulatory events in prostate cancer to inform the identification of additional therapeutic targets. Implications: This study develops a framework for identifying cancer drivers using prostate cancer ASE data, generates a comprehensive dataset of ASE in prostate cancer and highlights candidate targets in tumorigenesis and metastasis.

Year:

2026

PURPOSE Guidelines recommend offering germline testing to patients with advanced prostate cancer (PCa) to inform treatment and personal/familial cancer risk. We asked whether veterans affairs (VA) patients made informed decisions about germline testing after informed consent discussions with oncologists. METHODS We conducted a mixed-methods study of veterans with advanced PCa at the San Francisco VA. We audio recorded patient-oncologist germline testing discussions to assess oncologist communication concordance with National Comprehensive Cancer Network consent guidelines. Seven days afterward, we administered the Decisional Conflict Scale (DCS) and KnowGene scale to assess decisional conflict and germline testing knowledge, respectively, and interviewed veterans and caregivers to characterize decision making. We separately interviewed VA oncology and genetics providers for their perspectives on veterans' decision making. RESULTS Among 41 participants, 35 (85%) agreed to germline testing. The mean DCS score was 25/100 (higher = greater decisional conflict); 19% had scores >37.5, which is associated with decision delay. Recordings and surveys revealed that oncologists often did not communicate, and most patients lacked knowledge about key informed consent elements, particularly about potential harms, testing outcomes, and results disclosure. Interviews with patients, caregivers, and providers identified numerous patient decisional needs (decisional conflict, inadequate knowledge, unrealistic expectations, inadequate support/resources, and complex decision); barriers to patient decision making (inadequate oncologist training/bandwidth, limited access to educational resources, insufficient oncology/genetics workforce, and paternalistic culture); and facilitators (patient-centered communication, caregiver engagement, and trust in VA). CONCLUSION Although decisional conflict about germline testing was low, some patients made uninformed decisions and oncologists did not communicate all elements of informed consent according to guidelines. To promote patient-centered care, we recommend provider training about informed consent and shared decision making, increased oncology/genetics workforce capacity, and tailored patient-facing educational resources.

Year:

2025

To better understand veterans’ decisions about germline testing, we conducted a single-site, qualitative study of 32 veterans with advanced prostate cancer. Seven days after oncologist-patient discussions about germline testing, we conducted semistructured interviews with patients to explore their decision-making process using an interview guide. Four of 14 veterans with service-connected disability benefits for prostate cancer declined germline testing for fear of losing benefits because their livelihood depended on these benefits. All 18 veterans without service-connected benefits agreed to testing. Veterans declining germline testing based on this concern can lead to suboptimal cancer care because targeted treatments that could improve their outcomes may go unrecognized. Our findings contributed to new language in the Veterans Benefits Administration Compensation and Pension Manual clarifying that genetic testing showing hereditary predisposition is insufficient to deny service-connected benefits for conditions presumed to be caused by military exposures. Clinicians should communicate this protection when counseling veterans about genetic testing.

Year:

2024

Immunofluorescence staining of PD-L1+ CD68 myeloid cells in the bone biopsies. A. RNAscope staining of DAPI (cyan), CD68 (orange), PD-L1 (magenta), Tim3 (green), TIGIT (white) and overlay of bone marrow metastasis. CD68+ cells that co-express PD-L1 are indicated with arrow. Tim3+ cells are indicated with pointer. Scale bar, 20 μm. B. Scatterplot of PDL1+ CD68+ cell frequencies of tissue imaging data and PDL1+ CD14+ CD3-CD19- myeloid cell frequencies of CyTOF data from blood samples taken at the same timepoint (baseline, n=10 patients). R2 value is based on Pearson correlation. C. Scatterplot of TIM3+ CD68- cell frequencies on tissue imaging and TIM3+ CD3+ T cell frequencies of CyTOF data from blood samples taken at the same timepoint (baseline, n=10 patients). R2 value is based on Pearson correlation.

Year:

2024

Swimmer’s plot of treatments received. Number of radium-223 and pembrolizumab doses received are listed to the left and right of the bars, respectively. The brackets “[” and “]” represent the planned break period from radium-223 dosing with “[” representing cycle 3 day 28 and “]” representing cycle 4 day 1 when the interval between these was greater than 28 days. Patients could resume radium treatment at radiographic progression by PCWG2 criteria (“△”) if there were no new visceral metastases, but two patients (bars 7 and 13 below) resumed without confirmed radiographic progression.

Year:

2024

Kaplan-Meier estimates of time to treatment failure (TTF), radiographic progression-free survival (rPFS), and overall survival (OS) by A. baseline CD4+FoxP3- (effector) proportion above (high) vs. below (low) median. B. baseline CD8+ proportion above vs. below median. C. baseline CD8+ / CD4+FoxP3+ (Treg) ratio above vs. below median. N.B. Patients were event-free for 2 months as they need to have on treatment biopsy at week 8 of treatment.

Year:

2024

Swimmer’s plot of treatments received. Number of radium-223 and pembrolizumab doses received are listed to the left and right of the bars, respectively. The brackets “[” and “]” represent the planned break period from radium-223 dosing with “[” representing cycle 3 day 28 and “]” representing cycle 4 day 1 when the interval between these was greater than 28 days. Patients could resume radium treatment at radiographic progression by PCWG2 criteria (“△”) if there were no new visceral metastases, but two patients (bars 7 and 13 below) resumed without confirmed radiographic progression.

Year:

2024

The checkpoint immunotherapeutic pembrolizumab induces responses in a small minority of patients with metastatic castration-resistant prostate cancer (mCRPC). Radium-223 (R223) may increase immunogenicity of bone metastases and increase pembrolizumab (P) activity. In a randomized phase II study, we assessed the effect of R223+P compared with R223 on tumor immune infiltration, safety, and clinical outcomes in patients with mCRPC. The primary endpoint was differences in CD4 + and CD8 + T-cell infiltrate in 8-week versus baseline bone metastasis biopsies; secondary endpoints were safety, radiographic progression-free survival (rPFS), and overall survival (OS). Of the 42 treated patients (29 R223+P, 13 R223), 18 R223+P and 8 R223 patients had evaluable paired tumor biopsies. Median fold-change of CD4 + T cells was −0.7 (range: −9.3 to 4.7) with R223+P and 0.1 (−11.1 to 3.7) with R223 ( P = 0.66); for CD8 + T cells, median fold-change was −0.6 (−7.4 to 5.3) with R223+P and −1.3 (−3.1 to 4.8) with R223 ( P = 0.66). Median rPFS and OS was 6.1 (95% confidence interval: 2.7–11.0) and 16.9 months [12.7–not reached (NR)], respectively, with R223+P and 5.7 (2.6–NR) and 16.0 (9.0–NR), respectively, with R223. Although R223+P was well tolerated with no unexpected toxicity, the combination did not improve efficacy. High-dimensional flow cytometry demonstrated minimal immune modulation with R223, whereas R223+P induced CTLA-4 expression on circulating CD4 + T cells. Clinical responders possessed lower circulating frequencies of Ki67 + T and myeloid cells at baseline and higher circulating frequencies of TIM-3 + T and myeloid cells by week 9. Although R223+P did not induce T-cell infiltration into the tumor microenvironment, exhaustion of induced peripheral T-cell immune responses may dampen the combination's clinical activity.

Year:

2024

Kaplan-Meier estimates of time to treatment failure (TTF), radiographic progression-free survival (rPFS), and overall survival (OS) by A. CD4+FoxP3- (effector) proportion increase vs. decrease from baseline to 8-week biopsy. B. CD8+ increase vs. decrease. C. CD8+ / CD4+FoxP3+ (Treg) ratio increase vs. decrease. N.B. Patients were event-free for 2 months as they need to have on treatment biopsy at week 8 of treatment.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2022

Collaborators (18)

Lucia Kwak

Johns Hopkins University

UNITED STATES
View details

David A. Quigley

Assistant Professor

University of California, San Francisco

UNITED STATES
View details

Eliezer Van Allen

Professor

Harvard University

UNITED STATES
View details

Arun Wiita

Associate Professor

University of California, San Francisco

UNITED STATES
View details

Maxwell Meng

Professor

University of California, San Francisco

UNITED STATES
View details

Elad Ziv

Professor

University of California

UNITED STATES
View details

Chien-Kuang Ding

Assistant Professor

University of California, San Francisco

UNITED STATES
View details

Christopher J. Sweeney

University of Adelaide

AUSTRALIA
View details

Lawrence Fong

Fred Hutch Cancer Center

UNITED STATES
View details

Brandon Chen

University of California, San Francisco

UNITED STATES
View details

David Yang

Dana-Farber Cancer Institute

UNITED STATES
View details

Jeffrey Belkora

Associate Adjunct Professor

University of California, San Francisco

UNITED STATES
View details

Jingjing Li

University of California

UNITED STATES
View details

Atish Choudhury

Dana-Farber Cancer Institute

UNITED STATES
View details

Rahul Aggarwal

University of California

UNITED STATES
View details

Corynn Kasap

University of California, San Francisco

UNITED STATES
View details

Bradley McGregor

Dana-Farber Cancer Institute

UNITED STATES
View details

Sima P. Porten

-

UNITED STATES
View details